The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biswas, P. S.
Right arrow Articles by Rouse, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biswas, P. S.
Right arrow Articles by Rouse, B. T.
The Journal of Immunology, 2004, 172: 3736-3744.
Copyright © 2004 by The American Association of Immunologists

Mice Transgenic for IL-1 Receptor Antagonist Protein Are Resistant to Herpetic Stromal Keratitis: Possible Role for IL-1 in Herpetic Stromal Keratitis Pathogenesis1

Partha S. Biswas, Kaustuv Banerjee, Bumseok Kim and Barry T. Rouse2

Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Ocular infection with HSV may result in the blinding immunoinflammatory lesion stromal keratitis (SK). This represents a CD4+ T cell-mediated immunopathologic lesion in both humans and a mouse model. Early events in the pathogenesis that set the stage for SK are poorly understood. The present study evaluates the role of IL-1 using a transgenic mouse that overexpresses the IL-1 receptor antagonist (IL-1ra) protein. Such transgenic mice were markedly resistant to SK compared with IL-1ra-/- and C57BL/6 control animals. The resistance was shown to be the consequence of reduced expression of molecules such as IL-6, macrophage-inflammatory protein-2, and vascular endothelial growth factor, normally up-regulated directly or indirectly by IL-1. A critical event impaired in IL-1ra transgenic mice was vascular endothelial growth factor production with a consequent marked reduction in angiogenesis, an essential step in SK pathogenesis. Targeting IL-1 could prove to be a worthwhile therapeutic approach to control SK, an important cause of human blindness.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Herpes simplex virus infection is a major cause of vision loss (1). This results mainly from a chronic inflammatory reaction in the normally transparent and avascular cornea. A complex of humoral and cellular events is involved in the pathogenesis of stromal keratitis (SK),3 but the critical event responsible for clinically evident lesions is CD4+ T cell-mediated immunopathology (2, 3). Before the T cell-mediated immunoinflammatory phase, multiple events occur after virus infection that set the stage for the subsequent pathology. These events include the production of proinflammatory cytokines and chemokines and a prominent invasion of the cornea by polymorphonuclear leukocyte (PMN) (4, 5). The later response appears protective and helps clear virus (4, 5). However, PMN invasion also contributes to pathology because the cells are a major source of angiogenesis factors (6) and perhaps also damaging factors such as NO (7). Neovascularization represents a major step in SK pathogenesis, and multiple molecules are involved in this process (8). It is not clear how HSV infection, which in the mouse model is usually confined to the corneal epithelium, results in neovascularization into the underlying stroma. Thus, once a cell is productively infected by HSV, most cellular proteins cease production (9). Exceptions include IL-6 (10, 11) and probably IL-1 (12), which are briefly induced by HSV infection by mechanisms that remain undefined. These cytokines could represent key molecules that set off a cascade of events that culminate in the clinically evident immunoinflammatory lesions. After HSV infection, both IL-1 and IL-6 have been shown to be eminent by day 2 postinfection, to reach peak levels at day 10, and then to diminish over the next few days (13, 14). In consequence, counteracting IL-1 and IL-6 could be a valuable control measure at least if performed early after infection. The aim of this study was to determine whether inhibition of IL-1, as could be achieved by using a transgenic mouse that overexpressed the IL-1 receptor antagonist (IL-1ra), had an effect on SK pathogenesis. Such transgenic mice have been used in other inflammatory models and were shown to block IL-1 and diminish disease expression (15, 16, 17, 18). Our results with ocular infection with HSV demonstrate that IL-1ra transgenic (IL-1ra Tg) mice developed significantly milder disease and reduced corneal angiogenesis compared with IL-1ra-/- and C57BL/6 mice. This difference in disease phenotype was an indirect event and was shown to be the consequence of changed expression of molecules such as IL-6, macrophage-inflammatory protein-2 (MIP-2), and the angiogenesis factor vascular endothelial growth factor (VEGF) normally upregulated by IL-1 during an inflammatory process (19, 20, 21). Our results demonstrate that IL-1 production is a critical event in SK pathogenesis and that inhibiting this cytokine represents a valuable approach for disease control.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

IL-1ra Tg (T14 hemizygous line) and knockout mice were kindly provided by D. Hirsh (Department of Biochemistry and Molecular Biophysics, College of Physician and Surgeons, Columbia University, New York, NY). Wild-type female 4- to 5-wk-old C57BL/6 mice were purchased from Harlan Sprague Dawley (Indianapolis, IN). Animals were sex and age matched for all experiments. All manipulations involving the immunocompromised mice were performed in a laminar flow hood. To prevent bacterial superinfections, all mice received prophylactic treatment with sulfatrim pediatric suspension (Barre-National, Baltimore, MD). All experimental procedures were in complete agreement with the Association for Research in Vision and Ophthalmology resolution on the use of animals in research.

Virus

HSV-1 RE (obtained from R. Hendricks Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, PA) was used in the present study. The virus was propagated and titrated on monolayers of Vero cells (American Type Culture Collection, Manassas, VA; catalogue CCL81) using standard protocols (22). Infected Vero cells were harvested, titrated, and stored in aliquots at -80°C until used.

Corneal HSV-1 infection

Corneal infections of all mice groups were conducted under deep anesthesia induced by i.p. injection of avertin (Sigma-Aldrich, St. Louis, MO). Mice were scarified on their corneas with a 27-gauge needle, and a 4-µl drop containing the required dose of virus was applied to the eye and gently massaged with the eyelids.

Clinical observations and angiogenesis scoring

The eyes were examined on different days postinfection by a slit-lamp biomicroscope (Kowa, Nagoya, Japan), and the clinical severity of keratitis of individually scored mice was recorded, as described before (8). Angiogenesis severity was measured, as described previously (23). Briefly, a grade of 4 for a given quadrant of the circle represents a centripetal growth of 1.5 mm toward the corneal center. The score of the four quadrants of the eye was then summed to derive the neovascularization index (range 0–16) for each eye at a given point.

In vitro stimulation of corneal epithelial cell culture

Isolation of corneal epithelium cells was performed, as described before (24). Briefly, corneal buttons were incubated at 37°C in PBS containing 10 mM tetra sodium diaminetetracetate dehydrate (Sigma-Aldrich) for 45 min. After incubation, the epithelial cell layer was separated from the adjacent corneal tissue by gentle teasing with a fine forceps. The intact epithelial layer was washed several times in PBS, followed by treatment with collagenase D (Roche, Basel, Switzerland) at 37°C for 30 min. The disrupted epithelial cells were then passed through a 40-µm filter to make a single cell suspension. Cells were counted and suspended in F-12K medium (American Type Culture Collection) with 10% FCS and plated in 48-well tissue culture plates at 37°C in 5% CO2. Purity of cultured corneal epithelial cells was determined by flow cytometry using anti-K12 Ab (kindly provided by W. Kao, University of Cincinnati, Cincinnati, OH). The corneal epithelial cell culture yielded 75–80% purity.

Adherent monolayer of epithelial cells was stimulated with different doses of murine rIL-1{alpha} and rIL-1{beta} (R&D Systems, Minneapolis, MN) in serum-free F-12K medium for 24 and 48 h. After incubation, the supernatant was collected and stored at -80°C until further use. For blocking studies, different doses of anti-murine IL-1{alpha} Ab (BD PharMingen, San Diego, CA) were mixed with 800 pg (dose selected on the basis of dose-response curve) of IL-1{alpha}. Rat IgG was used as isotype control.

Corneal intrastromal injection assay

Corneal intrastromal injection was performed, as described before (25). Under direct stereomicroscopic observation, a nick in the epithelium and anterior stroma of mouse cornea was made with a one-half-inch 30-gauge needle with a 30° bevel in the mid periphery. Eight eyes were injected per group. The needle was introduced into the corneal stroma and advanced 1.5 mm to the corneal center. Two microliters of solution containing the required concentration of murine rIL-1{alpha} (100, 200, and 400 ng) (BD PharMingen) and anti-murine VEGF Ab (5 µg) (26) (R&D Systems) was forcibly injected into the stroma to separate the corneal lamellae and disperse the solution. PBS was used as control.

Subconjunctival inoculations

Subconjunctival inoculation of murine rIL-6 (50 ng) (27) (BD PharMingen) and anti-murine IL-6 Ab (5 µg/µl) (27) was performed, as described previously (27). Briefly, subconjunctival inoculations were done using a 2-cm 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate the perivascular region of conjunctiva and deliver 4 µl into the subconjunctival space. Control mice received PBS. Mice received murine rIL-6 1 day before corneal infection with HSV-1 RE.

Viral titration

Eye swabs were taken from the infected corneas (three mice/group) using sterile cotton swabs soaked in DMEM containing 10 IU/ml penicillin and 100 µg/ml streptomycin. All manipulations are done under sterile conditions. Swabs were stored in tubes containing serum-free DMEM at -80°C. For detection of virus, samples were thawed and vortexed. Duplicate samples (200 µl) were plated on Vero cells grown to confluence in 24-well plates at 37°C in 5% CO2 for 90 min. Medium was aspirated, and 500 µl of DMEM containing 1% low melting point agarose was added to each well. Titers were calculated as log10 PFU/ml as per standard protocol (22).

Histopathology

For histopathological analysis, eyes were extirpated and fixed in 10% buffered neutral formalin. Staining was performed with H&E (Richard Allen Scientific, Kalamazoo, MI).

RT-PCR

Total RNA from four corneas per time point was extracted by using Tri-reagent (Molecular Biology, Cincinnati, OH). Total RNA (1 µg) was reverse transcribed using murine leukemia virus reverse transcriptase (Life Technologies, Bethesda, MD) with oligo(dT) as primer (Invitrogen, San Diego, CA). All cDNA samples were aliquoted and stored at -20°C until further use. PCR was performed in PTC-100 Programmable Thermal Controller (MJ Research, Cambridge, MA) using Hot Start PCR Master Mix (Promega, Madison, WI). The primers used were murine GAPDH forward, CATCCTGCACCACCAACTGCTTAG, and reverse, GCCTGCTTCACCACCTTCTTGATG, and murine IL-1ra forward, TAGACATGGTGCCTATTGAC, and reverse, GAGGCTCACAGGACGGTCAG.

Flow cytometry

Single cell suspensions were prepared from four corneas at 24 and 48 h postinfection, as described elsewhere (28), with some modifications. Briefly, corneal buttons were incubated with collagenase D (Roche) for 60 min at 37°C in a humidified atmosphere at 5% CO2. After incubation, eyes were disrupted by grinding with a syringe plunger and passing through a cell strainer. Cells were washed and suspended in RPMI 1640 with 10% FBS. The Fc receptors on the cells were blocked with unconjugated anti-CD16/32 (BD PharMingen) for 30 min. Samples were incubated with FITC-labeled anti-Gr-1 Ab (clone RB6-8C5; BD PharMingen) and isotype controls for 30 min. All samples were collected on a FACScan (BD Biosciences, San Diego, CA), and data were analyzed using CellQuest 3.1 software (BD Biosciences).

Cytokine ELISA of corneal lysate

For preparation of corneal lysates, six corneas per time point were pooled and minced. All procedures were done on an ice bath. Minced pieces were collected in 1 ml of DMEM without FCS and homogenized using a tissue homogenizer (PRO Scientific, Monroe, CT) four times, 15 s each, with a gap of 1 min between homogenization to allow the sample to cool. The lysate was then clarified by centrifugation at 14,000 rpm for 5 min at 4°C. The supernatant was collected and used immediately or stored at -80°C until further use. Lysates were analyzed using a standard sandwich ELISA protocol. Anti-IL-6 capture and biotinylated detection Abs were from BD PharMingen (clone MP5-20F3), and standard murine rIL-6 was from R&D Systems. Anti-MIP-2 and anti-VEGF164 capture and biotinylated detection Abs and recombinant standards for murine MIP-2 and murine VEGF164 were from R&D Systems. The color reaction was developed using ABTS (Sigma-Aldrich) and measured with an ELISA reader (Spectramax 340; Molecular Devices, Sunnyvale, CA) at 405 nm. The detection limit was 2 pg/ml. Quantification was performed with Spectramax ELISA reader software version 1.2.

Quantitative real-time PCR

Total RNA from four corneas per time point was extracted by using RNeasy RNA extraction kit (Qiagen, Valencia, CA). Briefly, tissues were lysed in RLT buffer, and RNA was purified following manufacturer’s instructions (Qiagen). DNase treatment (Qiagen) was done to remove any contaminating genomic DNA. To generate cDNA, 1 µg of total RNA was reverse transcribed using murine leukemia virus reverse transcriptase (Life Technologies) with oligo(dT) as primer (Invitrogen), according to manufacturer’s instructions. All cDNA samples were aliquoted and stored at -20°C until further use.

Real-time PCR was performed using a DNA Engine Opticon (MJ Research). PCR was performed using SYBR Green I reagent (Qiagen), according to manufacturer’s protocol. PCR amplification of housekeeping gene, murine GAPDH, was done for each sample as a control for sample loading and to allow normalization between samples. A standard curve was constructed with PCR-II topo cloning vector (Invitrogen) containing the inserted same fragment amplified by the SYBR I system. PCR for each sample was analyzed in three dilutions in duplicate for both GAPDH and target gene. The target gene was then normalized to 106 copies of GAPDH control, and data were represented as copy numbers/106 GAPDH. The primers used were murine GAPDH forward, CATCCTGCACCACCAACTGCTTAG and reverse, GCCTGCTTCACCACCTTCTTGATG, and murine VEGFR-2 forward, TGTCAAGTGGCGGTAAAGG and reverse, CACAAAGCTAAAATACTGAGGACTTG.

Statistical analysis

A standard Student’s t test was used for statistical analysis.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
IL-1ra Tg mice show reduced SK and corneal angiogenesis

Three groups of genetically different mice, IL-1ra Tg, IL-1ra-/-, and wild-type C57BL/6, were evaluated clinically for the development of SK following HSV-1 (5 x 106 PFU) corneal infection over a 20-day test period. Naive and infected corneas of IL-1ra Tg mice demonstrated higher level of IL-1ra mRNA in comparison with wild-type control (Fig. 1). As shown in Fig. 2A, whereas the pattern and severity of SK in both IL-1ra-/- and wild-type C57BL/6 mice were similar (mean scores 3.5 and 2.7, respectively), SK in IL-1ra Tg mice was strikingly reduced (mean score of 1.4) (Fig. 2A). In addition, while 75% of eyes of IL-1ra-/- mice developed clinically evident lesions (score 3 or greater), only 25% of IL-1ra Tg mice developed such lesions (data not shown). Attempts to infect IL-1ra Tg mice with a higher virus dose (107 PFU) resulted in lethality, but still few developed SK of >=3 (data not shown). Histopathological analysis of representative eyes of IL-1ra Tg mice revealed mild inflammatory changes and cellular infiltrations in the corneal stroma and epithelium at day 20 postinfection (p.i.) (Fig. 2B). However, both IL-1ra-/- and C57BL/6 mice developed more severe inflammatory changes (Fig. 2B).



View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 1. Expression of corneal IL-1ra mRNA at various time points after HSV infection. At different time points p.i., corneas (n = 4) were isolated and total RNA was extracted using Tri-reagent. Total RNA (1 µg) was converted into cDNA, as described in Materials and Methods. PCR was performed in PTC-100 Programmable Thermal Controller (MJ Research). Murine GAPDH served as internal control. Lane M, m.w. marker; lane 1, C57BL/6 naive; lane 2, C57BL/6 day 2 p.i.; lane 3, C57BL/6 day 5 p.i.; lane 4, IL-1ra Tg naive; lane 5, IL-1ra Tg day 2 p.i.; lane 6, IL-1ra Tg day 5 p.i.

 


View larger version (58K):
[in this window]
[in a new window]
  		FIGURE 2. Reduced HSK severity in IL-1ra Tg mice. A, Mean lesion HSK score at day 20 p.i. of mice infected with 5 x 106 PFU HSV-1 RE. Each dot represents the HSK score from one eye. Horizontal bars and figures in the parentheses indicate the mean for each group. Data are compiled from two separate experiments consisting of eight eyes in each group. B, Mice were infected with 5 x 106 PFU HSV-1 RE. Mice were terminated at day 20 p.i., and eyes were processed for paraffin embedding. H&E staining was conducted on 6-µm sections. Magnification x200.

 
One characteristic of corneal HSV-1 infection is neovascularization into the normally avascular corneal stroma, an event deemed necessary for the full expression of SK (29). In comparison with the extent of angiogenesis following HSV infection in IL-1ra-/- and C57BL/6, the eyes of IL-1ra Tg mice revealed marked reduction of this process (Fig. 3, A and C). By day 20 p.i., the angiogenesis score was greater than 10 in 13 of 16 IL-1ra-/- eyes and 8 of 16 C57BL/6 mice (Fig. 3B), but only 4 of 16 eyes of IL-1ra Tg mice had such a score (Fig. 3B). Taken together, these results indicate that overexpression of IL-1ra protein led to diminished angiogenesis as well as SK.



View larger version (51K):
[in this window]
[in a new window]
  		FIGURE 3. IL-1ra Tg mice show reduced angiogenic response following HSV-1 infection at day 20 p.i. A, Kinetics of corneal neovascularization process in mice infected with 5 x 106 PFU HSV-1 RE. Angiogenesis scores were recorded, as mentioned in Materials and Methods, at indicated time points. Data are compiled from two separate experiments involving eight eyes per group and are expressed as mean ± SD. *, Statistically significant differences in angiogenesis score (p < 0.05) were observed between IL-1ra Tg mice to either IL-1ra knockout (K/O) or C57BL/6 mice. B, Angiogenesis scores for individual eyes of IL-1ra Tg, IL-1Ra-/-, and C57BL/6 mice infected with 5 x 106 PFU HSV-1 RE at day 20 p.i. Horizontal bars and figures show the mean for each group. Data are compiled from two separate experiments consisting of eight eyes per group. *, Statistically significant differences in angiogenesis score (p < 0.05) were observed between IL-1ra Tg mice to either IL-1ra K/O or C57BL/6 mice. C, At day 20 p.i., extensive growth of blood vessels can be seen in IL-1ra-/- and C57BL/6 mice infected with 5 x 106 PFU HSV-1 RE. IL-1ra Tg mice show minimum angiogenic sprouts near the limbal ring with the same dose.

 
PMN inflammatory response in IL-1ra Tg mice

A major event following ocular infection with HSV is a prompt PMN influx into the corneal stroma (4, 5). This reaction at 24 and 48 h p.i. was significantly less in IL-1ra Tg mice compared with either IL-1ra-/- or wild-type mice (Fig. 4, Table I). PMN are considered as involved in antiviral defense (4, 5). In line with this notion, viral clearance was impaired in IL-1ra Tg mice compared with IL-1ra-/- and wild-type mice (Table II). Accordingly, virus was present in ocular swabs for ~2 extra days in IL-1ra Tg mice (Table II).



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 4. Presence of abundant Gr-1+ cells in the cornea of IL-1ra-/- and C57BL/6 mice, but not in IL-1ra Tg mice at 48 h p.i. Single cell suspensions of corneal cells were prepared from four eyes at 24 and 48 h p.i. The cells were counted and stained with FITC-labeled anti-Gr-1 Ab, and numbers of Gr-1-positive cells were enumerated by FACS. Histogram is representative of one of three separate experiments. Filled and open histograms represent Gr-1+ cells at day 2 p.i. from uninfected and infected corneas, respectively.

 

View this table:
[in this window]
[in a new window]
  		Table I. IL-1ra Tg mice cornea has less number of Gr-1+ cells than IL-1ra knockout and C57BL/6

 

View this table:
[in this window]
[in a new window]
  		Table II. Delayed viral clearance in IL-1ra Tg mice in comparison with IL-1ra-/- and C57BL/6

 
One reason considered for the scant PMN response in IL-1ra Tg mice was that IL-1 must, in normal situations, serve to induce molecules that are directly or indirectly chemotactic for PMN. Based on the results of others (27, 30), prime candidates considered were IL-6 and MIP-2. Levels of these proteins were compared in the three mouse strains at various time points after HSV infection. Both IL-6 and MIP-2 protein levels in corneal extracts were significantly less in IL-1ra Tg mice compared with IL-1ra-/- and wild-type animals at all time points analyzed (Fig. 5). In addition, if murine rIL-6 protein was injected subconjunctivally into IL-1ra Tg animals 1 day before corneal infection, there was a ~4-fold increase in PMN influx in HSV-infected IL-1ra Tg mice compared with controls given PBS (Fig. 6A, Table III). Such eyes demonstrated a higher IL-6 level in comparison with PBS control at day 2 postinjection (data not shown). Furthermore, IL-6 reconstitution also resulted in significantly higher levels (p < 0.05) of the chemokine MIP-2 in corneal extracts (Fig. 6B).



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 5. Reduced IL-6 and MIP-2 protein levels in HSV-1-infected corneas of IL-1ra Tg mice. A and B, At indicated time points, six corneas/group were processed for measuring the IL-6 and MIP-2 protein levels. Levels of IL-6 and MIP-2 were estimated from supernatants of corneal lysates of mice infected with 5 x 106 PFU HSV-1 RE by an Ab capture ELISA, as outlined in Materials and Methods. Results are expressed as mean ± SD of three separate experiments (six corneas/time point). *, Statistically significant differences in IL-6 and MIP-2 level (p < 0.05) were observed between IL-1ra Tg mice to either IL-1ra knockout or C57BL/6 mice at all time points analyzed.

 


View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 6. Increased Gr-1+ cells and MIP-2 levels in murine rIL-6-reconstituted IL-1ra Tg corneas at 48 h p.i. A, Mice transgenic for IL-1ra protein received murine rIL-6 (50 ng) subconjunctivally 24 h before corneal HSV-1 infection. PBS was used as negative control. Single cell suspensions of corneal cells were prepared from four eyes at 24 and 48 h p.i. The cells were counted and stained with FITC-labeled anti-Gr-1 Ab, and numbers of Gr-1-positive cells were enumerated by FACS. Histogram is representative of one of three separate experiments. Shaded and open histograms represent Gr-1+ cells at day 2 p.i. from PBS and IL-6-reconstituted corneas of IL-1ra Tg mice, respectively. B, At 48 h p.i., six corneas each from IL-6-reconstituted and PBS control group were processed to measure the MIP-2 protein levels. Levels of MIP-2 were estimated from supernatants of corneal lysates of mice infected with 5 x 106 PFU HSV-1 RE by an Ab capture ELISA, as outlined in Materials and Methods. Results are expressed as mean ± SD of three separate experiments (six corneas/time point). *, Significant difference (p < 0.05) compared with PBS treatment.

 

View this table:
[in this window]
[in a new window]
  		Table III. Recombinant murine rIL-6-reconstituted IL-1ra Tg mice cornea has more Gr-1+ cells than PBS control following HSV-1 RE infection

 
To evaluate which corneal cells might act as a source of IL-6 upon IL-1 stimulation, corneal epithelial cell cultures were stimulated in vitro with different doses of rIL-1{alpha} and rIL-1{beta}. IL-1{alpha}, but not IL-1{beta}, could induce IL-6 production from corneal epithelial cells in a dose-dependent manner at 24 and 48 h (Fig. 7A). The presence of neutralizing Ab against murine IL-1{alpha}, but not control IgG, blocked the IL-6 production from these cells in a dose-dependent manner (Fig. 7B).



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 7. IL-1{alpha}-induced IL-6 production from corneal epithelial cells. A, Corneal epithelial cells were stimulated with different doses of murine rIL-1{alpha} for 24 and 48 h. Supernatants were collected, and levels of IL-6 production were measured by an Ab capture ELISA, as outlined in Materials and Methods. Results are expressed as mean ± SD of three separate experiments. *, Significant difference (p < 0.05) compared with medium control. B, Corneal epithelial cells were stimulated with 800 pg of murine rIL-1{alpha} along with different doses of anti-IL-1{alpha} Ab for 24 h. Supernatants were collected, and levels of IL-6 production were estimated by an Ab capture ELISA, as outlined in Materials and Methods. Results are expressed as mean ± SD of three separate experiments (six corneas/time point). *, Significant difference (p < 0.05) compared with rat IgG control. **, Significant difference (p < 0.05) compared with medium control.

 
Environment favorable for corneal angiogenesis is severely compromised in IL-1ra Tg mice

As noted above, IL-1ra Tg mice developed markedly diminished angiogenic responses compared with either IL-1ra-/- or wild-type controls. Protein levels of VEGF were significantly lower (p < 0.05) in IL-1ra Tg mice compared with IL-1ra-/- and C57BL/6 animals at all time points analyzed (Fig. 8A). In addition, real-time PCR demonstrated a significantly higher level of VEGFR-2 mRNA transcript in IL-1ra-/- and C57BL/6 mice than in IL-1ra Tg animals (Fig. 8B).



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 8. Reduced VEGF protein levels and diminished expression of VEGFR-2 mRNA expression in HSV-1 RE-infected corneas of IL-1Ra Tg mice. A, At indicated time points, six corneas/group were processed to measure the VEGF protein levels. Levels of VEGF were estimated from supernatants of corneal lysates of mice infected with 5 x 106 PFU HSV-1 RE by an Ab capture ELISA, as outlined in Materials and Methods. Results are expressed as mean ± SD of three separate experiments (six corneas/time point). *, Statistically significant differences in VEGF level (p < 0.05) were observed between IL-1ra Tg mice to either IL-1ra knockout (K/O) or C57BL/6 mice. B, At 2, 5, and 7 days postinfection, four corneas/group were processed for the extraction of cellular mRNA. Real-time PCR analysis was conducted to detect the VEGFR-2 mRNA expression in corneas of mice infected with 5 x 106 PFU of HSV-1, as described in Materials and Methods. Results are shown as mean ± SD of three separate experiments. *, Statistically significant differences (p < 0.05) were noted in the expression of VEGFR-2 between IL-1Ra Tg to IL-1ra K/O and C57BL/6 mice at 5 and 7 days p.i. aCopy number of the target gene was normalized to 106 copies of GAPDH.

 
Previous studies demonstrated that IL-1{alpha} could up-regulate the angiogenesis factor VEGF in human PBMC in vitro (20). To demonstrate the angiogenic activity of IL-1{alpha} in murine cornea, different doses of murine rIL-1{alpha} were injected intrastromally, and the extent of angiogenesis was measured at day 2 and 4 postinjection. Corneal ELISA revealed a significant increase in IL-1{alpha} level at day 2 postinjection in comparison with PBS control (data not shown). Interestingly, IL-1{alpha} induced a dose-dependent angiogenic response (Fig. 9). In such eyes, both IL-6 and VEGF protein levels were elevated (Fig. 10). Administration of neutralizing Ab against murine VEGF could abrogate IL-1{alpha}-induced angiogenesis, demonstrating the key involvement of VEGF in this process (Fig. 11A). Such eyes demonstrated diminished VEGF level in comparison with IgG control (data not shown). To rule out the possible involvement of IL-6 in the IL-1{alpha}-mediated corneal angiogenesis, anti-IL-6 Ab was administered with IL-1{alpha} protein. Interestingly, the presence of neutralizing Ab against IL-6 reduced, but did not abrogate, IL-1{alpha}-induced corneal angiogenesis (Fig. 11B).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 9. IL-1{alpha} induces angiogenesis in a corneal intrastromal injection assay. A, Different concentrations of rIL-1{alpha} (100, 200, and 400 ng) were injected intrastromally into C57BL/6 corneas (n = 8), and angiogenesis scoring was conducted on days 2 and 4 postinjection. VEGF (200 ng) was used as a positive control and PBS as negative control. Results expressed as mean ± SD. *, Significant difference (p < 0.05) compared with PBS treatment. B, Representative photographs of eyes at day 2 postinjection with 200 ng of IL-1{alpha} showing finer blood vessel development than that seen with the same dose of VEGF (open arrows). The PBS control showing no blood vessel development. Filled arrows indicate the site of intrastromal injection.

 


View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 10. IL-1{alpha} induces IL-6 and VEGF production in the cornea. A and B, Corneas of C57BL/6 mice were injected intrastromally with 200 ng of murine rIL-1{alpha}. Corneas were excised from mice after 48 h and processed for detection of IL-6 and VEGF from corneal lysates, as described in Materials and Methods. Results are expressed as mean ± SD for three separate experiments involving six corneas. *, Significant difference (p < 0.05) compared with PBS treatment.

 


View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 11. Neutralizing Ab against VEGF, but not IL-6, can abrogate IL-1{alpha}-induced angiogenesis in the cornea. A, Corneas (n = 8) of C57BL/6 mice were injected intrastromally with 200 ng of murine rIL-1{alpha} alone, 200 ng of murine rIL-1{alpha} and anti-murine VEGF (5 µg) Ab, anti-murine VEGF (5 µg) Ab only, and PBS. Angiogenesis scoring was conducted on days 2 and 4 postinjection. Results expressed as mean ± SD for three separate experiments. *, Significant difference (p < 0.05) compared with mice treated with IL-1{alpha} alone (200 ng). **, Significant difference (p < 0.05) compared with mice treated with PBS. B, Corneas (n = 8) of C57BL/6 mice were injected intrastromally with 200 ng of murine rIL-1{alpha} alone, 200 ng of recombinant murine rIL-1{alpha} and anti-murine IL-6 (5 µg) Ab, anti-murine IL-6 (5 µg) Ab only, and PBS. Angiogenesis scoring was conducted on days 2 and 4 postinjection. Results expressed as mean ± SD for three separate experiments. *, Significant difference (p < 0.05) compared with mice treated with anti-IL-6 Ab with IL-1{alpha}. **, Significant difference (p < 0.05) compared with mice treated with only anti-IL-6 Ab or PBS control.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This study deals with early events in the pathogenesis of the blinding immunoinflammatory lesion SK caused by ocular infection with HSV. Our results demonstrate that transgenic mice that overexpress the IL-1ra protein are markedly resistant to SK compared with control C57BL/6 mice. The resistance appeared to be the consequence of a reduced expression of molecules usually induced by IL-1, which in turn participate in inflammatory cell recruitment and angiogenesis. In the present study, we evaluate the critical role of IL-1 using a transgenic mouse that overexpresses IL-1ra protein. Thus, IL-1ra Tg mice had reduced levels of IL-6, the chemokine MIP-2, as well as the angiogenesis factor VEGF and its receptor VEGFR-2. In consequence, the IL-1ra Tg mice showed less PMN influx and neovascularization than did control C57BL/6 animals. Our results imply that blocking IL-1 activity could represent a valuable therapeutic approach to control SK.

One striking difference noted between C57BL/6 control and IL-1ra Tg mice was a marked difference in PMN invasion 2 days post-HSV infection. This early PMN response was shown previously to be in part responsible for viral clearance (4, 5). This viewpoint was also supported by the present studies. Thus, IL-1ra Tg mice, which expressed a diminished PMN response, also showed a delay in viral clearance. How IL-1 in normal infected mice causes PMN influx remains unclear. However, because IL-1 itself is not chemotactic for PMN (31), the effect must be indirect, with IL-1 inducing one or more chemokines. A likely candidate is MIP-2, because MIP-2-neutralized mice develop minimal PMN responses to ocular HSV infection (30). The results of the present study indicate that IL-1 did induce MIP-2, but this was an indirect consequence of IL-6 induction. In support, IL-1{alpha} was shown to induce IL-6 in vitro in corneal epithelial cells. In addition, MIP-2, as well as other chemokines, such as MIP-1{alpha} and monocyte chemoattractant protein-1, were shown by others to be induced by IL-6 (27, 32). Our studies also demonstrated that IL-1 was up-regulated in virus-infected corneal epithelial cells (data not shown). This observation as well as others (10, 11, 12) indicate that HSV infection results in the autocrine production of IL-1 as well as IL-6. This process may be brief because, as HSV infection proceeds, host mRNA synthesis and protein translation are inhibited in productively infected cells (9). However, IL-1 also drives IL-6 production by uninfected cells, which, together with that produced by infected cells themselves, sets off a cascade of events that result in PMN influx. Supporting the scheme, we could show that the provision of exogenous IL-6 intrastromally to the transgenic mice reconstituted the PMN invasion.

Although PMN play a protective function in HSV ocular infection, they also participate in lesion expression and act as a source of angiogenesis factors (6) as well as molecules such as NO (7) that damage corneal tissues. Thus, in line with the minimal early PMN response noted in IL-1ra Tg mice, such animals showed a marked reduction in angiogenesis compared with controls. One factor derived from PMN, as well as from other cell types involved in neovascularization, is VEGF (33, 34). We demonstrated that VEGF was significantly down-regulated in IL-1ra Tg mice in comparison with control animals. Similar observations were reported previously in a nonspecific model of ocular inflammation (35). The diminished VEGF response of transgenic mice may be explained by the fact that the presence of the IL-1ra suppressed IL-1-induced VEGF production from uninfected corneal cells such as PMN. Previously, HSV infection was shown to cause VEGF production, but not from the cells actually infected with virus (8). Conceivably, cytokines such as IL-1 released from infected cells explain the paracrine induction of VEGF. Supporting this scheme, the presence of IL-1ra suppressed the VEGF response. In addition, the angiogenic response induced in mice by intrastromal injection of IL-1 could be largely inhibited by anti-VEGF Ab. Furthermore, intrastromal injection of IL-1{alpha} was shown to induce VEGF in the cornea. These observations as well as others in tumor systems (20, 36) indicate that IL-1 can cause cells to produce VEGF.

Even though IL-1 produced from HSV-infected cells may act as an inducer for VEGF production, an additional VEGF stimulant appeared to be mediated by the cytokine IL-6. Thus, we demonstrated that corneal cells exposed to IL-1 in vitro produce IL-6, and IL-6 was shown previously to be a strong agonist for VEGF production (25, 37, 38). Further support that IL-1-induced angiogenesis depended in part on IL-6 production was the observation that it was partially blocked by anti-IL-6 Ab. The relative importance of the direct and indirect effect of IL-1 on VEGF production and angiogenesis remains to be evaluated.

Finally, our results demonstrated that corneal RNA samples from transgenic mice showed diminished VEGFR-2 levels measured by real-time PCR. In tumor systems, IL-1 was shown to up-regulate VEGFR-2 expression on endothelial cells (39), the latter known to be critical for pathological angiogenesis (40). Evidently, the absence of IL-1 activity, as occurred in IL-1ra Tg mice, results in reduced expression of VEGFR-2. The consequence is lack of stimulation for the endothelial cells to proliferate, resulting in reduced angiogenesis. However, it is not clear why transgenic mice demonstrated reduced VEGFR-2 expression. We believe there may be two possibilities: first, IL-1 may directly up-regulate VEGFR-2 expression on corneal endothelial cells, and blocking its activity by specific antagonist protein results in reduced receptor expression; second, reduced proliferation of endothelial cells as a consequence of diminished VEGF and inflammatory response in these mice. We are currently attempting to ascertain which of these two mechanisms accounts for the major effect of IL-1 on angiogenesis.

Taken together, our results support the hypothesis that the inflammatory milieu and angiogenic stimuli created early after infection play an important role in HSV-induced ocular lesions. An important participant of this environment is IL-1. Antagonizing the effect of IL-1 by a specific receptor antagonist protein abrogates the cascade of events that culminate in herpetic SK (HSK). This regulation is indirectly mediated by down-regulating various signaling molecules previously known to be important in HSK pathogenesis and corneal angiogenesis. It would seem that targeting IL-1 could prove to be a worthwhile therapeutic approach to control SK, an important cause of human blindness.


   Acknowledgments
 
We express our thanks to Dr. Udayasankar Kumaraguru and Christopher Pack for helpful suggestions and critical reading of the manuscript. The help of Amy Cupples is gratefully acknowledged.


   Footnotes
 
1 This work was supported by National Institutes of Health Grant EY05093. Back

2 Address correspondence and reprint requests to Dr. Barry T. Rouse, M409 Walters Life Sciences Building, University of Tennessee, Knoxville, TN 37996-0845. E-mail address: btr{at}utk.edu Back

3 Abbreviations used in this paper: SK, stromal keratitis; HSK, herpetic SK; IL-1ra, IL-1 receptor antagonist; IL-1ra Tg, IL-1ra transgenic; MIP, macrophage-inflammatory protein; p.i., postinfection; PMN, polymorphonuclear leukocyte; VEGF, vascular endothelial growth factor. Back

Received for publication October 17, 2003. Accepted for publication January 6, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Streilein, J. W., M. R. Dana, B. R. Ksander. 1997. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol. Today 18:443.[Medline]
  2. Russell, R. G., M. P. Nasisse, H. S. Larsen, B. T. Rouse. 1984. Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Invest. Ophthalmol. Visual Sci. 25:938.[Abstract/Free Full Text]
  3. Niemialtowski, M. G., B. T. Rouse. 1992. Phenotypic and functional studies on ocular T cells during herpetic infections of the eye. J. Immunol. 148:1864.[Abstract]
  4. Tumpey, T. M., S. H. Chen, J. E. Oakes, R. N. Lausch. 1996. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. J. Virol. 70:898.[Abstract]
  5. Thomas, J., S. Gangappa, S. Kanangat, B. T. Rouse. 1997. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J. Immunol. 158:1383.[Abstract]
  6. Lee, S., M. Zheng, B. Kim, B. T. Rouse. 2002. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J. Clin. Invest. 110:1105.[Medline]
  7. Daheshia, M., S. Kanangat, B. T. Rouse. 1998. Production of key molecules by ocular neutrophils early after herpetic infection of the cornea. Exp. Eye Res. 67:619.[Medline]
  8. Zheng, M., S. Deshpande, S. Lee, N. Ferrara, B. T. Rouse. 2001. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 75:9828.[Abstract/Free Full Text]
  9. Kwong, A. D., J. A. Kruper, N. Frenkel. 1988. Herpes simplex virus virion host shutoff function. J. Virol. 62:912.[Abstract/Free Full Text]
  10. Kanangat, S., J. S. Babu, D. M. Knipe, B. T. Rouse. 1996. HSV-1-mediated modulation of cytokine gene expression in a permissive cell line: selective up-regulation of IL-6 gene expression. Virology 219:295.[Medline]
  11. Paludan, S. R.. 2001. Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J. Virol. 75:8008.[Abstract/Free Full Text]
  12. Tran, M. T., D. A. Dean, R. N. Lausch, J. E. Oakes. 1998. Membranes of herpes simplex virus type-1-infected human corneal epithelial cells are not permeabilized to macromolecules and therefore do not release IL-1{alpha}. Virology 244:74.[Medline]
  13. Thomas, J., S. Kanangat, B. T. Rouse. 1998. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J. Interferon Cytokine Res. 18:681.[Medline]
  14. Staats, H. F., R. N. Lausch. 1993. Cytokine expression in vivo during murine herpetic stromal keratitis: effect of protective antibody therapy. J. Immunol. 151:277.[Abstract]
  15. Thompson, R. C., D. J. Dripps, S. P. Eisenberg. 1992. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int. J. Immunopharmacol. 14:475.[Medline]
  16. Kary, S., G. R. Burmester. 2003. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int. J. Clin. Pract. 57:231.[Medline]
  17. Cominelli, F., C. C. Nast, B. D. Clark, R. Schindler, R. Lierena, V. E. Eysselein, R. C. Thompson, C. A. Dinarello. 1990. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86:972.
  18. Mikuniya, T., S. Nagai, M. Takeuchi, T. Mio, Y. Hoshino, H. Miki, M. Shigematsu, K. Hamada, T. Izumi. 2000. Significance of the interleukin-1 receptor antagonist/interleukin-1{beta} ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration 67:389.[Medline]
  19. Yano, S., H. Nokihara, A. Yamamoto, H. Goto, H. Ogawa, T. Kanematsu, T. Miki, H. Uehara, Y. Saijo, T. Nukiwa, S. Sone. 2003. Multifunctional interleukin-1{beta} promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. Cancer Sci. 94:244.[Medline]
  20. Salven, P., K. Hattori, B. Heissig, S. Rafii. 2002. Interleukin-1{alpha} promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 16:1471.[Abstract/Free Full Text]
  21. Garat, C., W. P. Arend. 2003. Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-{kappa}B pathways. Cytokine 23:31.[Medline]
  22. Spear, P. G., B. Roizman. 1972. Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion. J. Virol. 9:143.[Abstract/Free Full Text]
  23. Dana, M. R., S. N. Zhu, J. Yamada. 1998. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea 17:403.[Medline]
  24. Lausch, R. N., S. H. Chen, T. M. Tumpey, Y. H. Su, J. E. Oakes. 1996. Early cytokine synthesis in the excised mouse cornea. J. Interferon Cytokine Res. 16:35.[Medline]
  25. Banerjee, K., P. S. Biswas, B. Kim, S. Lee, B. T. Rouse. 2004. CXCR2-/- mice show enhanced susceptibility to herpetic stromal keratitis: a role for IL-6-induced neovascularization. J. Immunol. 172:1237.[Abstract/Free Full Text]
  26. Zheng, M., D. M. Klinman, M. Gierynska, B. T. Rouse. 2002. DNA containing CpG motifs induces angiogenesis. Proc. Natl. Acad. Sci. USA 99:8944.[Abstract/Free Full Text]
  27. Fenton, R. R., S. Molesworth-Kenyon, J. E. Oakes, R. N. Lausch. 2002. Linkage of IL-6 with neutrophil chemoattractant expression in virus-induced ocular inflammation. Invest. Ophthalmol. Visual Sci. 43:737.[Abstract/Free Full Text]
  28. Deshpande, S., M. Zheng, S. Lee, K. Banerjee, S. Gangappa, U. Kumaraguru, B. T. Rouse. 2001. Bystander activation involving T lymphocytes in herpetic stromal keratitis. J. Immunol. 167:2902.[Abstract/Free Full Text]
  29. Zheng, M., M. A. Schwarz, S. Lee, U. Kumaraguru, B. T. Rouse. 2001. Control of stromal keratitis by inhibition of neovascularization. Am. J. Pathol. 159:1021.[Abstract/Free Full Text]
  30. Yan, X. T., T. M. Tumpey, S. L. Kunkel, J. E. Oakes, R. N. Lausch. 1998. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest. Ophthalmol. Visual Sci. 39:1854.[Abstract/Free Full Text]
  31. Calkins, C. M., D. D. Bensard, B. D. Shames, E. J. Pulido, E. Abraham, N. Fernandez, X. Meng, C. A. Dinarello, R. C. McIntyre, Jr. 2002. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. J. Endotoxin Res. 8:59.
  32. Yoshida, K., I. Ichimiya, M. Suzuki, G. Mogi. 1999. Effect of proinflammatory cytokines on cultured spiral ligament fibrocytes. Hear. Res. 137:155.[Medline]
  33. Kasama, T., K. Kobayashi, N. Yajima, F. Shiozawa, Y. Yoda, H. T. Takeuchi, Y. Mori, M. Negishi, H. Ide, M. Adachi. 2000. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin. Exp. Immunol. 121:533.[Medline]
  34. Scapini, P., F. Calzetti, M. A. Cassatella. 1999. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J. Immunol. Methods 232:121.[Medline]
  35. Moore, J. E., T. C. McMullen, I. L. Campbell, R. Rohan, Y. Kaji, N. A. Afshari, T. Usui, D. B. Archer, A. P. Adamis. 2002. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest. Ophthalmol. Visual Sci. 43:2905.[Abstract/Free Full Text]
  36. Saijo, Y., M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, T. Nukiwa. 2002. Proinflammatory cytokine IL-1{beta} promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J. Immunol. 169:469.[Abstract/Free Full Text]
  37. Nakahara, H., J. Song, M. Sugimoto, K. Hagihara, T. Kishimoto, K. Yoshizaki, N. Nishimoto. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48:1521.[Medline]
  38. Wei, L. H., M. L. Kuo, C. A. Chen, C. H. Chou, K. B. Lai, C. N. Lee, C. Y. Hsieh. 2003. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517.[Medline]
  39. Ristimaki, A., K. Narko, B. Enholm, V. Joukov, K. Alitalo. 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273:8413.[Abstract/Free Full Text]
  40. Ferrara, N., H. P. Gerber, J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669.[Medline]



This article has been cited by other articles:


Home page
 IOVSHome page
Y. Kondo, K. Fukuda, T. Adachi, and T. Nishida
Inhibition by a Selective I{kappa}B Kinase-2 Inhibitor of Interleukin-1-Induced Collagen Degradation by Corneal Fibroblasts in Three-Dimensional Culture
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4850 - 4857.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Nakao, Y. Hata, M. Miura, K. Noda, Y. N. Kimura, S. Kawahara, T. Kita, T. Hisatomi, T. Nakazawa, Y. Jin, et al.
Dexamethasone Inhibits Interleukin-1{beta}-Induced Corneal Neovascularization: Role of Nuclear Factor-{kappa}B-Activated Stromal Cells in Inflammatory Angiogenesis
Am. J. Pathol., September 1, 2007; 171(3): 1058 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. Duan, L. Remeijer, J. M. van Dun, A. D. M. E. Osterhaus, and G. M. G. M. Verjans
Granulocyte Macrophage Colony-Stimulating Factor Expression in Human Herpetic Stromal Keratitis: Implications for the Role of Neutrophils in HSK
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Kim, P. P. Sarangi, Y. Lee, S. Deshpande Kaistha, S. Lee, and B. T. Rouse
Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation
J. Leukoc. Biol., December 1, 2006; 80(6): 1405 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse
Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects
J. Immunol., September 15, 2006; 177(6): 4122 - 4131.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
D. J. J. Carr, J. Ash, T. E. Lane, and W. A. Kuziel
Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1.
J. Gen. Virol., March 1, 2006; 87(Pt 3): 489 - 499.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Heiligenhaus, H. F. Li, Y. Yang, S. Wasmuth, K. P. Steuhl, and D. Bauer
Transplantation of Amniotic Membrane in Murine Herpes Stromal Keratitis Modulates Matrix Metalloproteinases in the Cornea
Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4079 - 4085.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. S. Biswas, K. Banerjee, B. Kim, P. R. Kinchington, and B. T. Rouse
Role of Inflammatory Cytokine-Induced Cycloxygenase 2 in the Ocular Immunopathologic Disease Herpetic Stromal Keratitis
J. Virol., August 15, 2005; 79(16): 10589 - 10600.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Polcicova, P. S. Biswas, K. Banerjee, T. W. Wisner, B. T. Rouse, and D. C. Johnson
Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea
PNAS, August 9, 2005; 102(32): 11462 - 11467.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Kim, S. Lee, S. Suvas, and B. T. Rouse
Application of Plasmid DNA Encoding IL-18 Diminishes Development of Herpetic Stromal Keratitis by Antiangiogenic Effects
J. Immunol., July 1, 2005; 175(1): 509 - 516.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
P. S. Biswas, K. Banerjee, M. Zheng, and B. T. Rouse
Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein
J. Leukoc. Biol., October 1, 2004; 76(4): 868 - 875.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biswas, P. S.
Right arrow Articles by Rouse, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biswas, P. S.
Right arrow Articles by Rouse, B. T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS